About KRON
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. [Read more]
Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 63
Stock Exchange NASDAQ
Ticker Symbol KRON
Full Company Profile
Financial Performance
Financial Statements
Analyst Forecast
According to 2 analysts, the average rating for KRON stock is "Strong Buy." The 12-month stock price forecast is $4.13, which is an increase of 300.97% from the latest price.
Price Target
$4.13
(300.97% upside)
Analyst Consensus: Strong Buy
Stock Forecasts
News
Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation — — Company expects to provide an efficacy update on this expansion cohort in 1H 2025 — SAN MATEO, Calif. and CAM...
17 days ago - GlobeNewsWire
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
— KB-0742 continues to demonstrate a manageable safety and tolerability profile with no grade 3/4 neutropenia observed —
2 months ago - GlobeNewsWire
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other d...
2 months ago - GlobeNewsWire
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other d...
2 months ago - GlobeNewsWire
Kronos Bio Reports First-Quarter 2024 Financial Results
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new do...
3 months ago - GlobeNewsWire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half ...
5 months ago - GlobeNewsWire
How Does Kronos Stock Look After Its 15% Rise Last Week?
Kronos Worldwide KRO (NYSE: KRO), a titanium dioxide pigments (TiO2) producer and marketer, has gained around 15% in a week, considerably outperforming the broader Russell 2000 index which remains dow...
5 months ago - Forbes
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025
5 months ago - GlobeNewsWire
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced t...
5 months ago - GlobeNewsWire
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced pa...
5 months ago - GlobeNewsWire
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership team Company eliminates three executive officer roles and appoints new Executive Leadership team
7 months ago - GlobeNewsWire
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
Phase 1b portion of phase 1b/2 lanraplenib study in patients withrelapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2
8 months ago - GlobeNewsWire
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th...
8 months ago - GlobeNewsWire
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th...
9 months ago - GlobeNewsWire
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences
9 months ago - GlobeNewsWire
Kronos Bio Announces Plan to Optimize Resource Allocation, Restructure and Contain Costs Following Positive Preliminary Clinical Data from its KB-0742 Phase 1/2 Study
Strategic resource allocation to fully explore KB-0742's potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study
10 months ago - GlobeNewsWire
Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical studi...
10 months ago - GlobeNewsWire
Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting
Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting
10 months ago - GlobeNewsWire
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors
10 months ago - GlobeNewsWire
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of Hope Management to host con...
11 months ago - GlobeNewsWire
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that its...
1 year ago - GlobeNewsWire
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October 20...
1 year ago - GlobeNewsWire
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
Dr. Besman brings more than 25 years of regulatory affairs and drug development experienceand a track record of successfully advancing clinical programs Dr. Besman brings more than 25 years of regula...
1 year ago - GlobeNewsWire
Kronos Bio Announces Participation in Upcoming Investor Conferences
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th...
1 year ago - GlobeNewsWire
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML ...
1 year ago - GlobeNewsWire
